GAMMA Investing LLC lifted its position in Mesoblast Limited (NASDAQ:MESO - Free Report) by 1,174.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 85,513 shares of the company's stock after purchasing an additional 78,802 shares during the quarter. GAMMA Investing LLC owned about 0.07% of Mesoblast worth $1,067,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the company. Cubist Systematic Strategies LLC raised its holdings in shares of Mesoblast by 241.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 35,191 shares of the company's stock worth $697,000 after acquiring an additional 24,870 shares in the last quarter. Bank of America Corp DE increased its position in Mesoblast by 1,503.3% in the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock worth $5,756,000 after purchasing an additional 272,595 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Mesoblast by 86,566.7% during the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock valued at $51,000 after purchasing an additional 2,597 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in Mesoblast during the fourth quarter valued at $88,000. Finally, Jump Financial LLC purchased a new position in shares of Mesoblast in the 4th quarter worth $205,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald upgraded shares of Mesoblast to a "strong-buy" rating in a research report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $18.00.
Read Our Latest Research Report on Mesoblast
Mesoblast Price Performance
NASDAQ:MESO traded down $0.08 during midday trading on Thursday, hitting $11.69. 98,363 shares of the company traded hands, compared to its average volume of 273,102. The firm's fifty day moving average is $11.29 and its 200-day moving average is $14.02. Mesoblast Limited has a 12-month low of $5.78 and a 12-month high of $22.00. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.63 and a current ratio of 0.96.
About Mesoblast
(
Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Articles
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
